Detailed price information for Mediwound Ltd Ord Sh (MDWD-Q) from The Globe and Mail including charting and trades.
Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL® “These new findings are consistent with my ...
MediWound Ltd. announced the publication of a peer-reviewed post hoc analysis in the journal Wounds, based on data from its Phase II ChronEx clinical trial for patients with venous leg ulcers (VLUs).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback